{"name":"Taiwan Liposome Company","slug":"taiwan-liposome-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Lipotecan","genericName":"Lipotecan","slug":"lipotecan","indication":"Other","status":"discontinued"},{"name":"TLC590","genericName":"TLC590","slug":"tlc590","indication":"Other","status":"phase_3"},{"name":"AmBisome","genericName":"AmBisome","slug":"ambisome","indication":"Other","status":"marketed"},{"name":"Naropin","genericName":"Naropin","slug":"naropin","indication":"Other","status":"discontinued"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"DSP","genericName":"DSP","slug":"dsp","indication":"Metastatic breast cancer","status":"marketed"},{"name":"TLC599","genericName":"TLC599","slug":"tlc599","indication":"Treatment of various types of cancer","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Liposomal Amphotericin B","genericName":"Liposomal Amphotericin B","slug":"liposomal-amphotericin-b","indication":"Invasive fungal infections (aspergillosis, candidiasis, cryptococcosis)","status":"marketed"}]}],"pipeline":[{"name":"Lipotecan","genericName":"Lipotecan","slug":"lipotecan","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TLC590","genericName":"TLC590","slug":"tlc590","phase":"phase_3","mechanism":"TLC590 is a liposomal formulation designed to deliver its active pharmaceutical ingredient with improved pharmacokinetics and reduced systemic toxicity.","indications":[],"catalyst":""},{"name":"AmBisome","genericName":"AmBisome","slug":"ambisome","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DSP","genericName":"DSP","slug":"dsp","phase":"marketed","mechanism":"DSP is a liposomal doxorubicin formulation that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to improve drug targeting and reduce systemic toxicity.","indications":["Metastatic breast cancer","Ovarian cancer","Multiple myeloma"],"catalyst":""},{"name":"Liposomal Amphotericin B","genericName":"Liposomal Amphotericin B","slug":"liposomal-amphotericin-b","phase":"marketed","mechanism":"Liposomal amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause fungal cell death.","indications":["Invasive fungal infections (aspergillosis, candidiasis, cryptococcosis)","Empiric therapy for presumed fungal infections in febrile neutropenic patients","Leishmaniasis"],"catalyst":""},{"name":"Naropin","genericName":"Naropin","slug":"naropin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TLC599","genericName":"TLC599","slug":"tlc599","phase":"phase_3","mechanism":"TLC599 is a liposomal formulation of a chemotherapeutic agent.","indications":["Treatment of various types of cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLVlJc3JXdTZCR3pKMHhLclJMV0NhYksyQzJjZm5vOENGSUFQRzFIdHBvdzFvYXB3a3pSWGQ3RWtHZEpHMEJJcHZJXy1HdnNsejQ3TzV0bmZoenBMeFBCbjZwWERaekl3ZVJ4amcxNDlkZzJlM2V4VXgwLVdKSnhXYzFMSUVtcUkzNHlTei1IM254eF9TeHBQZzJR?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com","headline":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxQMWE1d0ZBY1AzTW9DdVF0YjE5OGl4Q2Zfd0lDY0dHTGdaRjk3X0tCZzBtSGV1NXpHNkRFcER6dnBDZWpuenNzS1VXc2JhTmZDWW9WaVFZNmJ6eVBoN2dpVFFTZFhtdXFHLTllUlRHdUxYNGxreUpLN2s3Z1ljUTBWZVpOVTEwRVBWRXctNUN4a2l6SmNFME5EUnZSRnFjMjRjNlpZMHBTVjhEY3hPNzJPNjFWMDlTTzV4LXh4VlJ6aFlHNElXcXlYcElVQ0U0dEc3VG83UzFpRmtSWk5BZEJKa0NaU1RrczV1NF9LS2c2RnpQSmo0cVRIeUdLS1ZwSTNldU8tYWVneWpFM1hITUdCNkFPR0ZrVXE0SXVfOWdwLWhxb1A2dGNEa2FSXzFPMHU1WUs5TA?oc=5","date":"2026-03-04","type":"pipeline","source":"prnewswire.com","summary":"Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight - prnewswire.com","headline":"Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPbTQ4dFNtN3ZWMHZHY1NwMmgzbVZvVzF0VElQNWVWWXVHQ1BjTXIxTmQ4VWY4RGdfVlFVYkU0LVBPbHZJQThMQmRHRGFYc19yYXZOeFJVSjh2UFNoR2hfT0tHZmZYdmdpVDJlOWtnQklZSERqdWxidWtvVjJCLWQyMVladEh4b0hsZ0lXZGRkWXFsc1FLU1hjWkdDdmx3WmNSQ0FfT1FGcmIxejI3Rnk3LWpCbm8yNS0xQmUtVFRsajhtTHdrWkZ6S3gwNTNxd1cxTkE3RWZnS2t6V3FLY2FUN2JQbGRrVWlMY1kzRkdRcUVVMms3WUhPQnhCbkwzeWxsRnFva0oyVEVjdUx6ZTAycFBQakh0dXVSRENRb2hfTjBoNEtUOTZGdGtNem5nemJBaEQ0elRhT245eG9H?oc=5","date":"2026-01-28","type":"trial","source":"GlobeNewswire","summary":"Chronic and Acute Pain Clinical Trial Pipeline Analysis: - GlobeNewswire","headline":"Chronic and Acute Pain Clinical Trial Pipeline Analysis:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOUmQybk9TX2VZZTFLQVZuek1GNl9ZdUU2eFlSZTdVTWpqZEtLU3M2MnRVLURYT0VfWVFBMk95YTZEOHF0ZHhDZmFIcU0yWHBQUWY3TTQybWFVWmUyMkNBdlNGZ3l0TzhOSUJwZklSd0VONXFLd3RTSER4dDV5T1lkeUNrYnM4NTZzb1ZzVUFualNPV25vSXRIaXU4U2l4YjVkQUlQeE5MeWtpd3FqaHk4TVJwVWYyRS0yb0piNU9vZ2ZFUG1zdTJCWEdYbG1nQW1PNW9CWF9fWkEyY1Nwek9IenlzcERnTk96SzNxOWdvSDVGeUFXOXdZRFRrcndESU01SkNPMVN3X1pmQnQ5V1A1WllCaUhrRzJLSHVTdTY0cF80QQ?oc=5","date":"2025-09-24","type":"trial","source":"prnewswire.com","summary":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight - prnewswire.com","headline":"Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE15TzJybWtPbnVOdS1qSUxlMG85SFV0NFJlTzNuTmxVWWhsUU5JLTJYRm5vNGtsc1VMU2lPNjdIOHZ2QVVkaTBzVDlNM29SS0hmQW5VWlJaTGQ3RTlUcmgwTU5XMU45Y1R5anlZa0NHc0dFajJ1RWZz?oc=5","date":"2025-06-11","type":"patent","source":"Insightace Analytic","summary":"Some Major Key Players In The Super Generics Market: - Insightace Analytic","headline":"Some Major Key Players In The Super Generics Market:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPbXRVTVowTW94NS1IeGMxa1hoZ21BeTZZSjc5QVRlY3pWS1k0V3J3ZjBhTTRsTVpiR01TSmctOFAyRHFjTHZiczQ0NkJCV3JKRGJzY1EwdWlzdlExMnRmalNzVHViNkh3NWNVdkdsRC1tQXRFMzFCTEFBZkVwVk43MXpRUHl2MVRfR1BqS05Jb2x5Vmc?oc=5","date":"2024-05-22","type":"pipeline","source":"Yahoo Finance","summary":"Taiwan Pharmaceutical Packaging Market 2024-2030: A $1.59 Billion Opportunity with Nasal and Pulmonary Drug Applications Anticipated to Register High Growth - Yahoo Finance","headline":"Taiwan Pharmaceutical Packaging Market 2024-2030: A $1.59 Billion Opportunity with Nasal and Pulmonary Drug Applications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNUWFaREFZWmpzdWNyNHl1Tk9KXzVXWHM5c3daLWJDNW9zMFFYdF9EUVZJYldXd2xEZEhqRENnbVhPTG9OT3dWc1ozMUp4NmFzc184VWFzVmJhcGhQY1E2aEc5d3hUNUZjYkROY09qTHhvS0p2RkRPdExIZGpnUEp3Q3c5dVB6OGdSWGFzV3hydHJEQWtfc2FjaVJ5NmNtYVhmU2hmMjR0RG1oZHJWcWtFbGRFUXpjWlRTRnYySjZOaDNRTGtHbHNwNTJ0UGNPQWRKbHd0M1E0cDliek5PcFA2TjFWR2F1Y182WDVjbGc1VndzMlZvNVowZkFnZVlYbjRqZmxYNjd4dkJzZw?oc=5","date":"2022-06-13","type":"trial","source":"prnewswire.com","summary":"Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain - prnewswire.com","headline":"Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPN3ZXWGNrQ081UE9zSWhRdE1JTURkbG9FWkRtSEFqSGVNWTV4R1pfWUVhWi1CYXY3d2tacF9lTW9vSkRoSFQ0eV9EU2hkTWRrZWZFeHBmMjVkOFB4aWpQVzMzanIycnctMzFRYkpOdHJ2eUI3N1lCWjAyWXcxZEUxa1RyQlYtNHZtSXpUTnFZRzdLYXU2SHJOOUxLLWRmYjUwdGN5MkgtZjRCblQ4RUNOcUpaS0VwVEI2Q3FnQQ?oc=5","date":"2021-07-05","type":"pipeline","source":"GlobeNewswire","summary":"TLC Announces Details of Stock Swap Transactions - GlobeNewswire","headline":"TLC Announces Details of Stock Swap Transactions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQbXpuQlF0TkZ2TG1jQ20xRm9KYnBTTk1OcWhraDhYRGh0dUdzM3BZRGVHWTJydmdKY3JUZ3NZazZwUDZsLUpPNVBCa1lJNkxHSjRqNkp6QUtTMHBadEtWNmp6YmZNazBrcVpLMklXU2xzSXl4Q3FPWFVkMDlBNm5jMWY5em5rMHJHOVMwaWROUWVscUdCeU9oeGZvdFR5X0tjb0FKbFBpUzlPbV9raF9rQ2I5X3NIbmJlQnBacVZ4OEpvMUI5clJySjBxU1M0cTBs?oc=5","date":"2019-06-25","type":"deal","source":"BioSpace","summary":"TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product - BioSpace","headline":"TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQNWVGQnpweXcwVVRIU3lOelhZSnhodHdsTVJWRENfZ0M5SnFLUkxKZEpqbWYyVTRXS2w2Y3BRekVXME9KQWFBb2NKRVduekZMVkg0VlBzRGxoLUs5cXdQaXA1a3VJWldQOTczLVJQSUxFMUN0c3ktQ0dBZlR6cnZoU1p4c1Y2NC1uREdlNjhjT2YwWWhOZGpadmZnRQ?oc=5","date":"2018-02-20","type":"pipeline","source":"BioSpectrum Asia","summary":"Taiwan Liposome Company files for $50M US IPO - BioSpectrum Asia","headline":"Taiwan Liposome Company files for $50M US IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOQ0QzcWtOc1V3TmZkd2ZsZjktY3VQclpPekw0c3Q5OGpfVDNfMXY4aEZxa0k4RG9UcEtwbTVXYjZzbG5WVWNRSXpiaC1HV0F4MUc2VVg1LXhjMmJxVVRCRDlySEFxRkpZWExHOUxZWjU5Rl9xaHJYSlQwYkp1b0R3Nk9VbC1aNUVtczhKRXBENGd2aHhtdll2U2FYRk93bGEyRlE?oc=5","date":"2016-07-05","type":"pipeline","source":"Fierce Pharma","summary":"Exclusive: George Yeh of Taiwan Liposome talks 4+4 and biotech growth - Fierce Pharma","headline":"Exclusive: George Yeh of Taiwan Liposome talks 4+4 and biotech growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPcmZmdXc2eFd3UTdWeVpyTk9Ea0NKRmp4MFpKZy02bXkwV2pQTzU0MWRUR1Z2ODdOTy1SQlRRdEJac3EyXzN2b29aVWR6MzVSQmJoTERMSTNhYzNMVWs4YWxCbEZZZ2pKTkt1b1lteVNNWDNJaEdNWHlWTTRUZmlwWi1tNGFmVFhHdEdpLXc0dkg5cWhkSExNZ0EtTWdvSURWekRnMXEwLUtyYlVyajVOQ0RaM1M5c2g2cnV1aVBR?oc=5","date":"2016-06-24","type":"trial","source":"Fierce Pharma","summary":"Taiwan Liposome PhI/II trial on acupuncture-type arthritis candidate fully enrolled - Fierce Pharma","headline":"Taiwan Liposome PhI/II trial on acupuncture-type arthritis candidate fully enrolled","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"discontinued":2,"phase_3":2,"marketed":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}